our Premium Content: News alerts, weekly reports and conference planners

DRUG:

IDC-G305

News alerts, weekly reports and conference planners

Company:

Merck (MSD)

Drug class:

Immunostimulant, NY ESO 1 inhibitor, TLR agonist

Related drugs:

RG6180 (4)

AV-GBM-1 (3)

SV-BR-1-GM (2)

tirvalimogene teraplasmid (2)

Histone H3.3-K27M Neoantigen Vaccine Therapy (1)

AdHER2/neu DC Vaccine (0)

bioengineered allogeneic immune cells (0)

velimogene aliplasmid (0)

interferon alpha 2b (0)

dasiprotimut-T (0)

Bria-OTS (0)

CD25hi Treg depleted DLI (0)

recombinant human papillomavirus bivalent vaccine (0)

CodaLytic (0)

dendritic cell vaccine (0)

cancer vaccine MUC-1 (0)

autologous dendritic cell vaccine leaded with autologous tumor cell lysate (0)

DI Leu16 IL-2 (0)

DNAJB1-PRKACA peptide vaccine (0)

Dendritic cell renal cell carcinoma fusion vaccine (0)

FR Alpha Peptide Vaccine (0)

GVAX leukemia vaccine (0)

GVAX lung cancer vaccine (0)

types 6, 11, 16, 18 (0)

human papillomavirus 9-valent vaccine, recombinant (0)

H1299 cell lysate with iscomatrix adjuvant vaccine (0)

H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant (0)

HER-2 pulsed DC1 (0)

HER2- and HER3-primed dendritic cells (0)

IDH1R132H peptide vaccine (0)

autologous γδ T lymphocytes (0)

MMP9FS (0)

KRAS peptide vaccine (0)

axalimogene filolisbac (0)

MVA-BN-Brachyury IV vaccine (0)

MVI-816 (0)

autologous dendritic cell vaccine (0)

NY-ESO-1 Iscomatrix (0)

NY-ESO-1 combined with MPLA vaccine (0)

Poly-ICLC matured DC adjuvanted NY-ESO-1/Melan-A-MART-1 peptide vaccine (0)

PolyPEPI 1018 (0)

rilimogene galvacirepvec (0)

live attenuated bacillus Calmette-Guerin (0)

Tri-Ad5 (0)

CMV-MVA vaccine (0)

UV1 (0)

Undisclosed VLP vaccine (0)

Undisclosed ovarian cancer vaccine (0)

alpha-tocopheroloxyacetic acid (0)

allogeneic K562-GM tumor cell vaccine (0)

allogeneic Myeloma GM-CSF Vaccine (0)

alpha-lactalbumin vaccine (0)

PG2 (0)

autologous Tcm cellular immunotherapy (0)

autologous formalin-fixed tumor vaccine (0)

mammaglobin-A DNA vaccine (0)

TG4010 (0)

STAT-401 (0)

multi-epitope melanoma peptide (0)

neoantigen DNA vaccine (0)

neoantigen peptide vaccine (0)

nonavalent HPV vaccine (0)

ADU-741 (0)

oral therapeutic vaccine V3-X (0)

p.DOM-WT1-126 DNA vaccine (0)

pING-hHER3FL (0)

polyvalent vaccine-KLH conjugate (0)

CDX-1401 (0)

CMN-001 (0)

self-amplifying RNA cancer vaccine (0)

MultiTAA T cell therapy (0)

N201 (0)

NY-ESO-1 TCR (0)

NY-ESO-1 TCR-T cell therapy (0)

›

A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (NCT02015416)

Phase 1

Immune Design

Completed

Phase 1

Immune Design

Completed

Last update posted :

08/17/2017

Initiation :

11/01/2013

Primary completion :

12/01/2016

Completion :

03/01/2017

CTAG1B

CTAG1B expression

IDC-G305 • glucopyranosyl lipid A (G100)

IDC-G305

Trials

Trials